Title: CD10 and Das1: a biomarker study using immunohistochemistry to subtype gastric
intestinal metaplasia
Version: 2 Date: 03 Jan 2022
Reviewer's report:
Topic 1: “Innovation”
: Again, I'm afraid that using two markers, CD10 and DAS-1 does not seem very interesting
because they already are well-established markers. Likewise, methodology such as multiple
single gland analysis by digital quantification is not strong enough to make up for the weakness
of the small number of cases, especially if you try to analyze the risk of IM subtype in GC
development.
Topic 2: “Diagnosis of IM subtypes, mixed IM and hybrid IM”
:  "The utility of CD10 and Das1 staining in combination is to group not only subtypes but also
help in risk prediction for progression to gastric cancer."
For the above response from the authors,  I feel that this study does not provide strong evidence
(Again, about 20 cases of GCs and control seems too small to make any conclusion.
I understand the study has been finished and it is impossible to include additional cases and do
it all over again. I feel sorry, but I'm not very convinced about the conclusion of the study.
Title: CD10 and Das1: a biomarker study using immunohistochemistry to subtype gastric
intestinal metaplasia
Version: 2 Date: 03 Jan 2022
Reviewer's report:
Topic 1: “Innovation”
: Again, I'm afraid that using two markers, CD10 and DAS-1 does not seem very interesting
because they already are well-established markers. Likewise, methodology such as multiple
single gland analysis by digital quantification is not strong enough to make up for the weakness
of the small number of cases, especially if you try to analyze the risk of IM subtype in GC
development.
Topic 2: “Diagnosis of IM subtypes, mixed IM and hybrid IM”
:  "The utility of CD10 and Das1 staining in combination is to group not only subtypes but also
help in risk prediction for progression to gastric cancer."
For the above response from the authors,  I feel that this study does not provide strong evidence
(Again, about 20 cases of GCs and control seems too small to make any conclusion.
I understand the study has been finished and it is impossible to include additional cases and do
it all over again. I feel sorry, but I'm not very convinced about the conclusion of the study.
Please review this paper.
user
Title: CD10 and Das1: a biomarker study using immunohistochemistry to subtype gastric
intestinal metaplasia
Version: 2 Date: 03 Jan 2022
Reviewer's report:
Topic 1: “Innovation”
: Again, I'm afraid that using two markers, CD10 and DAS-1 does not seem very interesting
because they already are well-established markers. Likewise, methodology such as multiple
single gland analysis by digital quantification is not strong enough to make up for the weakness
of the small number of cases, especially if you try to analyze the risk of IM subtype in GC
development.
Topic 2: “Diagnosis of IM subtypes, mixed IM and hybrid IM”
:  "The utility of CD10 and Das1 staining in combination is to group not only subtypes but also
help in risk prediction for progression to gastric cancer."
For the above response from the authors,  I feel that this study does not provide strong evidence
(Again, about 20 cases of GCs and control seems too small to make any conclusion.
I understand the study has been finished and it is impossible to include additional cases and do
it all over again. I feel sorry, but I'm not very convinced about the conclusion of the study.
assistant